Timothy Eugene Sullivan - 31 Dec 2024 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Financial Officer
Signature
/s/s David Watson, attorney-in-fact for Timothy Sullivan
Issuer symbol
APLS
Transactions as of
31 Dec 2024
Net transactions value
+$154,826
Form type
4
Filing time
03 Jan 2025, 16:09:09 UTC
Previous filing
19 Apr 2024
Next filing
14 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $15,578 +1,042 +1.3% $14.95 80,216 31 Dec 2024 Direct
transaction APLS Common Stock Options Exercise $139,248 +10,054 +13% $13.85 90,270 31 Dec 2024 Direct
holding APLS Common Stock 70,396 31 Dec 2024 The Timothy E Sullivan Irrevocable Trust of 2023 F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -1,042 -4.2% $0.000000 23,958 31 Dec 2024 Common Stock 1,042 $14.95 Direct F2
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -10,054 -11% $0.000000 84,946 31 Dec 2024 Common Stock 10,054 $13.85 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities are held by The Timothy E Sullivan Irrevocable Trust of 2023. Patrick O. Collins is the trustee of The Timothy E Sullivan Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Timothy E Sullivan Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.
F2 This option was granted on February 16, 2018 and fully vested.
F3 This option was granted on February 8, 2019 and fully vested.